Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Nov;172(15-16):337-345.
doi: 10.1007/s10354-022-00912-7. Epub 2022 Feb 8.

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity

Affiliations
Review

Cerebrospinal fluid kappa free light chains as biomarker in multiple sclerosis-from diagnosis to prediction of disease activity

Harald Hegen et al. Wien Med Wochenschr. 2022 Nov.

Abstract

Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system that shows a high interindividual heterogeneity, which frequently poses challenges regarding diagnosis and prediction of disease activity. In this context, evidence of intrathecal inflammation provides an important information and might be captured by kappa free light chains (κ-FLC) in the cerebrospinal fluid (CSF). In this review, we provide an overview on what is currently known about κ‑FLC, its historical development, the available assays and current evidence on its diagnostic and prognostic value in MS. Briefly, intrathecal κ‑FLC synthesis reaches similar diagnostic accuracy compared to the well-established CSF-restricted oligoclonal bands (OCB) to identify patients with MS, and recent studies even depict its value for prediction of early MS disease activity. Furthermore, detection of κ‑FLC has significant methodological advantages in comparison to OCB detection.

Keywords: Clinically isolated syndrome; FLC index; Oligoclonal bands; Progression; Relapse.

PubMed Disclaimer

Conflict of interest statement

H. Hegen has participated in meetings sponsored by, received speaker honoraria or travel funding from Bayer, Biogen, Merck, Novartis, Sanofi-Genzyme, Siemens, Teva, and received honoraria for acting as consultant for Biogen, Novartis and Teva. K. Berek has participated in meetings sponsored by and received travel funding from Roche, Teva and Biogen. F. Deisenhammer has participated in meetings sponsored by or received honoraria for acting as an advisor/speaker for Alexion, Almirall, Biogen, Celgene, Genzyme-Sanofi, Merck, Novartis Pharma, Roche, and Teva. His institution has received research grants from Biogen and Genzyme Sanofi. He is section editor of the MSARD Journal (Multiple Sclerosis and Related Disorders).

Figures

Fig. 1
Fig. 1
Schematic illustration of the molecular structure of immunoglobulins and free light chains. B cells produce (a) intact immunoglobulins and (b) in excess free light chains. Both immunoglobulins and FLC serve as biomarker for B cell activity. a Immunoglobulins consist of two identical heavy chains (blue) and two identical light chains (green). Each heavy chain consists of four immunoglobulin domains linked by a hinge region. Differences in the structure of the constant regions (CH1, CH2 and CH3) determine the isotype (IgG, M, A, D, E) and subclass of the immunoglobulin (e.g., IgG1–4), while the variable domain (VH) contributes to the antigen binding site. Each light chain consists of two immunoglobulin domains. Differences in the structure of the constant region (CL) determine the isotype of free light chain (either κ or λ), while the variable domain (VL) contributes to the antigen binding site. Accordingly, both the heavy chains and light chains form the amino-terminal variable (V) regions responsible for antigen recognition; the carboxyl-terminal constant (C) regions mediate effector functions. b Free light chains show the same structure as light chains bound within the intact immunoglobulin. FLC have a molecular weight of approximately 24 kD and consist of the two immunoglobulin domains CL and VL. Differences in the structure of the constant region (CL) determine the isotype of the free light chain (either κ or λ). Whereas κ‑FLC mainly exist in the form of monomers, λ‑FLC are present as covalent dimers. CH constant heavy chain domain, CL constant light chain domain, Fab fragment antibody binding, Fc fragment crystallisable, FLC free light chain, VH variable heavy chain domain, VL variable light chain domain

Similar articles

Cited by

References

    1. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359(9313):1221–1231. - PubMed
    1. Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–173. - PubMed
    1. Arrambide G, Tintore M, Espejo C, Auger C, Castillo M, Río J, et al. The value of oligoclonal bands in the multiple sclerosis diagnostic criteria. Brain. 2018;141(4):1075–1084. - PubMed
    1. Ontaneda D, Tallantyre E, Kalincik T, Planchon SM, Evangelou N. Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis. Lancet Neurol. 2019;18(10):973–980. - PubMed
    1. Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020 doi: 10.1016/j.amjmed.2020.05.049. - DOI - PMC - PubMed

MeSH terms